Fate Therapeutics (FATE) Tops Q2 EPS by 5c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.29), $0.05 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $1.91 million versus the consensus estimate of $850.68 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Voya Financial estimates Q2 alternative investment pre-tax loss of $9M-$19M
• PriceSmart (PSMT) Misses Q3 EPS by 4c, Beats on Revenue